RayKnowChina Research Map
Shortlist0

RecruitingB-cell acute lymphoblastic leukaemiaPhase 2

Registered title, quoted from ClinicalTrials.gov

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06718244, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 16 years to 70 years; sex: all

    Registered eligibility fields

  2. Newly diagnosed Ph-negative B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry) in CR1 (with <5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease)after induction chemotherapy or consolidation chemotherapy.

    Inclusion criterion 3

  3. ECOG score of 0-1 at screening

    Inclusion criterion 2

  4. Aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN);

    Inclusion criterion 7

    Alanine aminotransferase (ALT) ≤3 times ULN;

    Inclusion criterion 8

    Total bilirubin ≤2 times ULN (for patients with Gilbert's syndrome, total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN);

    Inclusion criterion 9

    Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL/min (using the Cockcroft-Gault formula);

    Inclusion criterion 10

    International Normalized Ratio (INR) ≤1.5 times ULN and activated partial thromboplastin time (APTT) ≤1.5 times ULN;

    Inclusion criterion 11

  5. HBe-Ab and/or HBc-Ab positive with HBV-DNA levels above the lower limit of quantification;

    Exclusion criterion 6

    HCV-Ab positive;

    Exclusion criterion 7

    HIV antibody positive;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06718244, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age between ≥16 and ≤70 years at screening, no gender restrictions
  • ECOG score of 0-1 at screening
  • Newly diagnosed Ph-negative B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry) in CR1 (with <5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease)after induction chemotherapy or consolidation chemotherapy.
  • Newly diagnosed Ph-positive B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry or BCR-ABL1 >0.01% detected by qPCR) in CR1 (with <5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease) .
  • At diagnosis of B-ALL,CD19 expression of leukemic cells is positive by flow cytometry in bone marrow or peripheral blood.
  • Appropirate organ function, meeting the following criteria:
  • Aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN);
  • Alanine aminotransferase (ALT) ≤3 times ULN;
  • Total bilirubin ≤2 times ULN (for patients with Gilbert's syndrome, total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN);
  • Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL/min (using the Cockcroft-Gault formula);
  • International Normalized Ratio (INR) ≤1.5 times ULN and activated partial thromboplastin time (APTT) ≤1.5 times ULN;
  • Left ventricular ejection fraction (LVEF) ≥50%;
  • Minimum pulmonary reserve, with oxygen saturation >91% on room air;
  • Meets leukapheresis standard of the study center, with no contraindications for blood cell separation;
  • Voluntarily agrees to participate in this study and signs on the informed consent form(ICF).

Exclusion Criteria:

  • Received CAR-T cell therapy before screening;
  • Inherited bone marrow failure syndrome(IBMFS) or any other known bone marrow failure syndromes;
  • Active systemic autoimmune diseases requiring treatment;
  • Any of the following conditions:
  • HBsAg and/or HBeAg positive;
  • HBe-Ab and/or HBc-Ab positive with HBV-DNA levels above the lower limit of quantification;
  • HCV-Ab positive;
  • TP-Ab positive;
  • HIV antibody positive;
  • EBV-DNA or CMV-DNA levels above the lower limit of quantification;
  • Active infection at screening.
  • Any other malignancy within the past five years before screening, excluding cases where the patient has been disease-free for more than 5 years after curative treatment or has a low risk of relapse as assessed by the investigator;
  • Any of the following cardiac conditions:
  • NYHA Class III or IV congestive heart failure;
  • Severe arrhythmia requiring treatment;
  • Uncontrolled hypertension or pulmonary hypertension despite standard therapy;
  • Unstable angina;
  • Myocardial infarction, bypass surgery, or stent placement within six months before cell retransfusion;
  • Clinically significant valvular disease;
  • Other cardiac conditions deemed unsuitable by the investigator;
  • History of epilepsy, cerebellar disease, or other active central nervous system disorders;
  • Uncontrolled diabetes;
  • History of symptomatic deep vein thrombosis or pulmonary embolism within six months before screening that is not well controlled;
  • History of hypersensitivity to any component of the investigational product.
  • Received a live vaccine within six weeks before screening;
  • Life expectancy of less than three months;
  • Participation in another interventional clinical trial and receiving investigational drugs within three months (for unapproved drugs) or within five half-lives (for approved drugs) before cell infusion, or plans to participate in another clinical trial or receive anti-cancer therapy outside the study protocol during the study period;
  • Other conditions deemed unsuitable for participation in this clinical trial by the investigator.

Quoted from ClinicalTrials.gov, NCT06718244, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06718244, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06718244